L-Dobixin 20

Adults:

When Doxorubicin HCl is used as a single agent, the dose is 60 to 75 mg/m2 given intravenously every 21 days. In combination therapy, the dose is 40 to 75 mg/m2 given intravenously every 21 to 28 days. Doxorubicin HCl should be discontinued in patients who develop signs or symptoms of cardiomyopathy, and the dose should be reduced in patients with hepatic impairment. As an intravenous injection, Doxorubicin HCl is given through a central intravenous line, or through a secure and free-flowing peripheral venous line containing 0.9% Sodium Chloride Injection, USP, 0.45% Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP. The injection runs over 3 to 10 minutes. If erythematous streaking appears along the vein proximal to the site of infusion, or if facial flushing occurs, the rate of administration should be decreased. As an intravenous infusion, Doxorubicin HCl is given only through a central catheter. Management of Suspected Extravasation: Doxorubicin HCl should be discontinued if the patient feels a burning or stinging sensation, or if there is other evidence of perivenous infiltration or extravasation. Confirmed or suspected extravasation is managed as follows. The needle should be left in place until attempts have been made to aspirate the extravasated fluid. The line should not be flushed, and pressure should not be applied to the site. Ice should be applied to the site intermittently for 15 min, 4 times a day, for 3 days. If the extravasation is in an extremity, the extremity should be elevated. In adults, administration of dexrazoxane should be considered. Incompatibility with Other Drugs: Doxorubicin hydrochloride should not be admixed with other drugs. A precipitate may form if Doxorubicin HCl is mixed with heparin or fluorouracil. Contact with alkaline solutions should be avoided, as these can lead to hydrolysis of Doxorubicin hydrochloride.